Back to Search Start Over

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma

Authors :
Patrick P.C. Boor
Maurice P.H.M. Jansen
Jaco Kraan
Dave Sprengers
Maikel P. Peppelenbosch
Jaap Kwekkeboom
Lisanne Noordam
Jean C. A. Helmijr
Zhouhong Ge
Gastroenterology & Hepatology
Medical Oncology
Source :
Translational Oncology, Translational Oncology, 14(7):101073. Neoplasia Press, Translational Oncology, Vol 14, Iss 7, Pp 101073-(2021)
Publication Year :
2020

Abstract

Highlights • In paired analysis CTCs were detected in 27% and ctDNA in 77% of HCC patients. • The TERT promoter mutation C228T was present in all patients with one or more ctDNA mutations, or detectable CTCs. • CtDNA (or TERT C228T) positivity was associated with macrovascular invasion and poor survival of advanced HCC patients.<br />Background and aims Circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) may be used for diagnostic or prognostic purposes in patients with hepatocellular carcinoma (HCC). We aim to determine whether CTCs or ctDNA are suitable to determine oncogenic mutations in HCC patients. Methods Twenty-six mostly advanced HCC patients were enrolled. 30 mL peripheral blood from each patient was obtained. CellSearch system was used for CTC detection. A sequencing panel covering 14 cancer-relevant genes was used to identify oncogenic mutations. TERT promoter C228T and C250T mutations were determined by droplet digital PCR. Results CTCs were detected in 27% (7/26) of subjects but at low numbers (median: 2 cells, range: 1–15 cells) and ctDNA in 77% (20/26) of patients. Mutations in ctDNA were identified in several genes: TERT promoter C228T (77%, 20/26), TP53 (23%, 6/26), CTNNB1 (12%, 3/26), PIK3CA (12%, 3/26) and NRAS (4%, 1/26). The TERT C228T mutation was present in all patients with one or more ctDNA mutations, or detectable CTCs. The TERT C228T and TP53 mutations detected in ctDNA were present at higher levels in matched primary HCC tumor tissue. The maximal variant allele frequency (VAF) of ctDNA was linearly correlated with largest tumor size and AFP level (Log10). CtDNA (or TERT C228T) positivity was associated with macrovascular invasion, and positivity of ctDNA (or TERT C228T) or CTCs (≥ 2) correlated with poor patient survival. Conclusions Oncogenic mutations could be detected in ctDNA from advanced HCC patients. CtDNA analysis may serve as a promising liquid biopsy to identify druggable mutations.

Details

ISSN :
19365233
Volume :
14
Issue :
7
Database :
OpenAIRE
Journal :
Translational oncology
Accession number :
edsair.doi.dedup.....36783bf7b0ede0be0c84ee4674b68a5e